These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30935915)

  • 1. Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment.
    Amore E; Manca ML; Ferraro M; Valenti D; La Parola V; Di Vincenzo S; Gjomarkaj M; Giammona G; Bondì ML; Pace E
    Int J Pharm; 2019 May; 562():351-358. PubMed ID: 30935915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
    Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment.
    Amore E; Ferraro M; Manca ML; Gjomarkaj M; Giammona G; Pace E; Bondì ML
    Nanomedicine (Lond); 2017 Oct; 12(19):2287-2302. PubMed ID: 28868971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ICS not indicated in the early stage].
    Einecke D
    MMW Fortschr Med; 2015 Dec; 157(21-22):85. PubMed ID: 26960883
    [No Abstract]   [Full Text] [Related]  

  • 7. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
    Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
    Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of ICS/LABA on COPD treatment].
    Shibata Y
    Nihon Rinsho; 2016 May; 74(5):827-32. PubMed ID: 27254954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
    Xia N; Wang H; Nie X
    PLoS One; 2015; 10(9):e0137904. PubMed ID: 26378450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncovering the regional localization of inhaled salmeterol retention in the lung.
    Bäckström E; Hamm G; Nilsson A; Fihn BM; Strittmatter N; Andrén P; Goodwin RJA; Fridén M
    Drug Deliv; 2018 Nov; 25(1):838-845. PubMed ID: 29587546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease.
    Chapman KR; Arvidsson P; Chuchalin AG; Dhillon DP; Faurschou P; Goldstein RS; Kuipers AF;
    Can Respir J; 2002; 9(3):178-85. PubMed ID: 12068339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
    Lung; 2006; 184(4):217-22. PubMed ID: 17006748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of salmeterol xinafoate in the treatment of COPD.
    Mahler DA; Donohue JF; Barbee RA; Goldman MD; Gross NJ; Wisniewski ME; Yancey SW; Zakes BA; Rickard KA; Anderson WH
    Chest; 1999 Apr; 115(4):957-65. PubMed ID: 10208192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
    Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
    Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium versus salmeterol in COPD.
    Schembri S
    N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714655
    [No Abstract]   [Full Text] [Related]  

  • 20. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA; Hawes HG; Doig CJ; Johnson MW; Yokoba M; Wilde ER
    Chest; 2010 Mar; 137(3):558-65. PubMed ID: 19820074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.